Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535041 | 0.87 | CES1 (0.54) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL51367 | 0.86 | CES1 (0.64) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL30293214 | 0.85 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL8748892 | 0.85 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL27976185 | 0.85 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL31412115 | 0.85 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL28533260 | 0.85 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| Cesium SCHEMBL9566054 | 0.85 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL28016131 | 0.85 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL28232885 | 0.85 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20040192697-A1 | Pyrrolopyridine potassium channel openers | ABBOTT LABORATORIES | 2004-09-30 | — | — | US | disclosed |
| US-20040122218-A1 | Pyrrolopyridine potassium channel openers | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | ABBOTT LABORATORIES | 2002-10-10 | — | — | US | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | CES1 736/4885CES2 2157/4885AKR1B1 305/4885 |
| US-20040122218-A1 | Pyrrolopyridine potassium channel openers | KCNJ2, KCNN1, KCNN2 | CES1 2261/4885CES2 3547/4885AKR1B1 605/4885 |
| US-20030199578-A1 | Naphthalene amides as potassium channel openers | KCNJ2, KCNN2, KCNJ1 | CES1 2560/4885CES2 1510/4885AKR1B1 466/4885 |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | CES1 1642/4885CES2 2933/4885AKR1B1 123/4885 |
| US-20040192697-A1 | Pyrrolopyridine potassium channel openers | KCNJ2, KCNN1, KCNN2 | CES1 2261/4885CES2 3547/4885AKR1B1 605/4885 |
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | CES1 1642/4885CES2 2933/4885AKR1B1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.